News

RapAdmin

Harvard researchers followed 111,467 US health professionals from the Nurses’ Health Study and the Health Professionals Follow-Up Study for more than 30 years, asking about leisure activity every two years. Over 2.4 million person-years they recorded 38,847 deaths. Total activity and most individual activities were linked to lower mortality, with walking, running, racquet sports, rowing or callisthenics, and weight training each tied to roughly 11 to 17% lower risk at the highest levels. Swimming was the exception and showed no association. Most benefits leveled off at modest weekly doses. The new contribution is a “variety score,” the number of different activities a person did regularly. Even after accounting for total activity, people in the top variety group had 19% lower all-cause mortality than those in the bottom group. Because the study is observational, it cannot prove that variety itself causes longer life.

Exercise guidelines are built around volume: 150 minutes of moderate activity a week, or 75 minutes of vigorous activity. A new analysis from the Harvard T.H. Chan School of Public Health asks a different question. Does it matter how many kinds of activity you do, and not just how much?

The researchers drew on two of the longest-running health cohorts in the world. More than 70,000 female nurses and 40,000 male health professionals reported their weekly time on walking, jogging, running, cycling, lap swimming, racquet sports, stair climbing, rowing or callisthenics, and weight training. They did this every two years from 1986 to about 2020, with a median of 13 reports per person. That repetition matters. A single baseline questionnaire captures a snapshot. Thirteen capture a habit.

The first finding confirms what earlier research suggested. Almost every activity was linked to lower risk of death, and most of the benefit came early. For walking, the curve flattened at about 7.5 MET-hours a week, or roughly two hours of brisk walking. For stair climbing it flattened at a very small dose, around a handful of flights a day. Tennis and other racquet sports reached their plateau at about 5 MET-hours a week. Past these points, more of the same activity added little.

Swimming was the outlier. Even heavy swimmers showed no lower mortality than non-swimmers. The authors suspect a measurement problem: an hour of gentle breaststroke and an hour of hard intervals look the same on a questionnaire.

The headline result concerns variety. Each person earned a point for every activity done consistently above a low threshold, usually 20 minutes a week. People in the top fifth for variety, who typically did three to four different activities, had 19% lower all-cause mortality than people in the bottom fifth. This held after statistical adjustment for total activity. The link was strongest for respiratory deaths, which were 41% lower, and was also clear for cardiovascular disease (17% lower) and cancer (13% lower). The two factors also added up: people high in both total activity and variety had 21% lower mortality than people low in both.

The plateau finding offers a plausible explanation. If each activity’s benefit saturates quickly, spreading the same total effort across several activities lets each one deliver its early, steep gains. Different activities also train different systems: endurance work builds aerobic capacity, resistance training preserves muscle and bone, and racquet sports add speed, balance and social contact.

The caveats are real. Variety and total activity were closely correlated, and self-reported activity is measured imprecisely, so the variety score may partly be picking up true total activity that the questionnaires missed. People who can do many different activities are probably healthier, fitter and better off to begin with. The participants were mostly white health professionals. Nothing here was randomized.

Even so, the advice that follows is cheap, safe and easy to act on: keep moving, and do it in more than one way.

Actionable Insights

  • Spread your activity across at least three or four types. The top variety group had a hazard ratio of 0.81, meaning 19% lower risk of death. Compared with the lowest group’s crude death rate of about 23 per 1,000 people per year, that works out to roughly 4 fewer deaths per 1,000 people per year. As a rough estimate under common aging-curve assumptions (mine, not the authors’), a lifelong 19% lower risk translates to about 2 extra years of life.
  • Walking does a lot of work. The top walking group had 17% lower mortality (HR 0.83), with the benefit mostly reached by about two hours a week.
  • Add resistance training. Regular weight training was linked to 13% lower mortality (HR 0.87), with a plateau near 7.5 MET-hours a week, about 75 minutes at a typical vigorous effort.
  • Consider a racquet sport. Tennis or squash was linked to 15% lower mortality (HR 0.85), plateauing at about 45 minutes a week.
  • Take the stairs. Even small daily amounts were linked to 10% lower risk.
  • Do not rely on swimming alone, at least as it is usually reported. It showed no clear benefit here, possibly because questionnaires cannot capture swimming intensity.
  • For scale: these are modest effects for any one person (an approximate Cohen’s d of about 0.1). Their value lies in being cheap, safe and cumulative.

Context and Source

  • Open Access Paper: Physical activity types, variety, and mortality: results from two prospective cohort studies, 20 January 2026.
  • Institutions: Harvard T.H. Chan School of Public Health (Departments of Nutrition and Epidemiology); Channing Division of Network Medicine, Brigham and Women’s Hospital and Harvard Medical School; with co-authors at Chongqing Medical University (China) and Yonsei University (South Korea)
  • Country: United States (lead institution)
  • Journal: BMJ Medicine, 2026
  • Impact evaluation: BMJ Medicine received a Journal Impact Factor of 9.3 in the June 2026, therefore this is a Medium impact journal.

RapAdmin

Two toxicologists at Maastricht University argue that the public and regulatory distinction between healthy food and toxic food does not survive scrutiny, and they illustrate this with ten short examples. Their central claim is that mild toxicity is often the mechanism of benefit rather than its opposite. Flavonoids appear to work partly through reactive chemistry that activates cellular defense pathways. High-dose vitamin B6 supplementation can produce nerve damage resembling B6 deficiency because the supplemented form competes with the active form. Natural compounds dominate dietary exposure to plant-defense chemicals, undercutting the assumption that natural equals safe. The authors also note a regulatory asymmetry: health claims demand rigorous trial evidence while risk regulation proceeds on precaution alone. They propose a graded concept of health risk to mirror how toxic risk is handled.

The paper opens with food tasters in ancient Egypt and Rome, employed to die so that rulers would not. The authors call them early toxicologists, with a wink, and the point they build from it is serious: for most of human history the test for whether food was safe was whether the person who ate it survived. We have better tools now, but the underlying category, safe versus poisonous, turns out to be far less tidy than either consumers or regulators behave as though it is.

The argument runs through ten short vignettes. Several are familiar to anyone who follows the field. The belief that natural compounds are inherently safe is unfounded, and the authors lean on a well-known 1990 estimate that the overwhelming majority by weight of pesticides in the American diet are chemicals that plants manufacture themselves. Chemophobia and its mirror image, an uncritical affection for anything labeled natural, are presented as emotional responses rather than evidence-based positions.

The more interesting material concerns hormesis. This is the observation that many compounds show a biphasic dose response: harmful at high doses, beneficial at low ones. The conventional regulatory model assumes a straight line from high-dose animal data down to real-world exposure, which ignores that cells have evolved machinery to detoxify and adapt. The authors argue that low-level stress is not a watered-down version of poisoning but a qualitatively different thing, an invitation for the body to upgrade its defenses.

Flavonoids are their worked example. These compounds are marketed as antioxidants, which suggests they neutralize damage. The authors point to a different picture. Once oxidized, flavonoids become reactive toward thiol groups, which a toxicologist would ordinarily flag as a damage mechanism. That reactivity activates Nrf2, a transcription factor that switches on a broad set of protective genes. The protective effect outlasts and exceeds anything simple radical scavenging could provide. The supposed toxicity is the delivery mechanism for the benefit.

The vitamin B6 example is the cleanest in the paper. Severe deficiency causes nerve damage. So does high-dose supplementation, which looks paradoxical until you notice that supplements almost always contain pyridoxine, which the body must convert into the active form. At high concentrations, the unconverted form appears to compete with the active one at the enzymes that need it. Too much of the supplement produces a functional shortage of the vitamin.

Two more threads deserve attention. The authors note that food and drug interactions are discussed almost entirely as hazards, when some combinations are beneficial. And they argue that the 1948 definition of health as complete wellbeing has outlived its usefulness, proposing instead that health is the ability to adapt. If that reframing is right, then the goal of a health-promoting diet is not to minimize all stress but to improve the capacity to handle it, which is a different target and would need different measurements.

The closing line is the authors’ own summary: the bitter taste of toxins becomes sweeter if toxicity leads to healthiness. It is a good line. Whether it is a good basis for deciding what to put in your body is a separate question, and the paper does not answer it.

Actionable Insights

This is an opinion piece. It contains no trial, no dose-response curve, and no quantitative outcome. That said, four points have practical teeth.

  1. Vitamin B6 has a real and low ceiling. The paper describes the mechanism but gives no number. The number exists: European regulators concluded in 2023 that the relationship between excess vitamin B6 intake and peripheral neuropathy is well established, set a reference point of 50 mg/day from case-control data, and established a tolerable upper intake level of 12 mg/day for adults. That revision halved the prior limit of 25 mg/day set in 2000, and the US National Academy of Medicine still uses 100 mg/day, a point critics of the revision have pressed. Most people do not approach these levels from food; regular users of high-dose supplements do. If you take a B-complex, read the label. Many contain 25 to 100 mg. Practical move: prefer the active form, pyridoxal-5-phosphate, over pyridoxine if you supplement at all, since the proposed mechanism of harm is specific to the unconverted form. www.pubmed.gov
  2. The hormesis framing supports interventions you can actually dose, and those are mostly not pills. Exercise, heat and cold exposure, and caloric restriction are the best-characterized hormetic stressors in humans, with dose-response curves that are at least partly understood. The flavonoid version of the same logic is far less mapped. The paper itself lists five unanswered questions for applying hormesis: optimal dose, frequency, duration, timing, synergy between stimuli, kinetics of the response, modification by age and sex, and whether adverse effects occur. Until those are answered for a given compound, “a little toxicity is good for you” is a hypothesis, not a dosing protocol. Note the direction this cuts: it argues against megadosing polyphenol supplements, not for it, because the benefit sits in a window and more is not better.
  3. Take the asymmetry seriously in both directions. The authors are right that health claims face a higher evidentiary bar than risk claims. The practical consequence for a consumer is the opposite of what the framing suggests: an authorized health claim is relatively trustworthy precisely because the bar is high, while the absence of a claim tells you little. Treat unclaimed benefits as unproven rather than as suppressed truth.
  4. Flag food-drug interactions in both directions with your prescriber. The paper’s examples include flavonoids enhancing corticosteroid response and grapefruit juice assisting cortisol replacement by altering drug-metabolizing enzymes. The same enzyme modulation that helps in one case causes harm in another. A beneficial interaction is still an interaction and still needs monitoring.

Context and Source

  • Open Access Paper: Exploring health and toxicity in food choices: 10 examples navigating the gray area, published 5 January 2024
  • Article type: Mini Review..
  • Institutions: University College Venlo, Maastricht University; Department of Pharmacology and Toxicology, Faculty of Health, Medicine and Life Sciences, Maastricht University
  • Country: Netherlands
  • Journal: Frontiers in Nutrition
  • Impact evaluation: The impact score of this journal is 5.5, evaluated against a typical high-end range of 0-60+ for top general science, therefore this is a Medium impact journal.

RapAdmin

A new preclinical study suggests that hyperactive mTOR signaling damages brain blood vessels in Alzheimer’s disease by disrupting the proteins that regulate RNA processing. Researchers examined purified cerebral microvessels from mouse models of both amyloid plaque accumulation and tau tangle pathology, alongside postmortem human cortical tissue. In untreated Alzheimer’s model mice, advancing pathology depleted two key RNA-binding proteins, hnRNP E1 and hnRNP D1, by up to 78 percent in brain capillaries while impairing stimulus-evoked cerebral blood flow. Chronic treatment with the mTOR inhibitor rapamycin partially restored these vascular RNA-regulatory proteins and rescued blood flow responses toward healthy baseline levels. In human brain tissue, lower levels of hnRNP L and hnRNP E1 correlated with more advanced Alzheimer’s staging. While preliminary and not yet peer-reviewed, these findings identify vascular RNA regulation as a potentially reversible driver of age-related neurovascular decline.

For years the case against mTOR in Alzheimer’s has been strong but oddly incomplete. Suppress the pathway with rapamycin and blood flow improves, the blood-brain barrier holds together, and memory gets better in mouse models. What nobody could say was which molecular switch mTOR was flipping inside the vessel wall.

This preprint proposes an answer: RNA-binding proteins. These are the proteins that decide which messenger RNAs get spliced, stabilized, shipped and translated. In the brains of people with Alzheimer’s, large proteomic surveys have repeatedly flagged RNA-processing machinery as among the most disease-associated signatures, but that work looked at brain tissue as a whole, dominated by neurons.

The team looked instead at purified microvessels. In mice carrying a human amyloid mutation, two members of the hnRNP family were markedly reduced in vessels at 12 months. Rapamycin brought both partway back. The size of these shifts was unusually large for a biology experiment, which is partly a sign of a real effect and partly a sign of small groups.

Two details raise the finding above a single-model curiosity. First, the defect was compartment-specific. When the same proteins were measured in whole brain lysates, amyloid pathology left them unchanged. The problem lives in the vasculature. Second, the same pattern showed up in a completely different mouse, one driven by mutant tau rather than amyloid. In those animals, rapamycin also improved the blood flow surge that normally follows whisker stimulation, a direct readout of neurovascular coupling.

There is also a twist in the timing. At 6 months, before overt disease, the proteins were not depleted at all. One was actually elevated, and rapamycin pushed the other higher still. Only at 12 months did the deficit appear. The authors read this as an early compensatory response that eventually fails, and they note the obvious implication: the same drug may do different things depending on when it is given.

The big idea here is unifying: vascular aging and RNA splicing failure in Alzheimer’s disease are not separate problems.Rather, chronic mTOR overactivation disrupts RNA-binding networks specifically inside brain blood vessels, choking off nitric oxide signaling and accelerating neurodegeneration. Because rapamycin reversed these vascular deficits in mice, targeting mTOR-regulated RNA homeostasis offers a promising, though still preclinical, strategy to protect the aging brain’s blood supply.

Insights

  1. The vascular compartment is where the signal lives. In whole brain lysates, the key protein was unchanged by disease. If you follow the mTOR-and-Alzheimer’s literature, this argues that vascular endpoints like cerebral blood flow and neurovascular coupling are the ones worth watching, not bulk brain measures.
  2. Effect sizes in the mouse data are large. The disease effect at 12 months corresponds to a Cohen’s d of roughly 4 to 10 for one protein and 2 to 4 for the other, meaning the groups barely overlap. With four to six mice per group, these estimates are badly inflated and will likely shrink on replication, but the direction is consistent across two models.
  3. Timing appears to matter and may cut both ways. At 6 months the same intervention moved these proteins in the opposite direction from the 12-month result. Any assumption that “earlier is better” with mTOR inhibition is not supported by this dataset.
  4. The relevant human clinical testing is still early. Aware and colleagues gave 1 mg/day rapamycin for four weeks to cognitively normal adults aged 45 to 65, stratified by APOE genotype, with cerebral blood flow by 3T arterial spin labeling as the primary endpoint. Twenty-three completed, 9 APOE4 carriers and 14 non-carriers. Blood flow rose in the sample overall by 3.08 mL/100 g/min and in carriers specifically by 4.68, with regional increases above 15 percent and the largest changes in precuneus and parietal lobe. The hippocampus moved in the same direction but did not reach significance. Non-carriers showed no significant blood flow change. For scale, the authors note that a 52-week aerobic exercise program raised hippocampal blood flow by 4.09 mL/100 g/min in hypertensive carriers while controls declined by 2.08, so the magnitude is in the range of a year of structured exercise. Plasma pTau-217 and serum amyloid A stayed within the healthy range and were unchanged.
  5. For individuals focused on brain longevity, the practical takeaway is that preserving endothelial function and nitric oxide bioavailability is central to cognitive aging. Lifestyle interventions that naturally pulse mTOR down and support endothelial nitric oxide offer immediate, low-risk options. Regular aerobic exercise, time-restricted eating, maintaining insulin sensitivity, and avoiding chronic caloric excess all temper baseline mTOR overactivity while directly strengthening neurovascular coupling

Context and Source Evaluation

  • Open Access paper: mTOR disrupts cerebrovascular RNA regulatory networks in Alzheimer’s disease, September 16, 2026
  • Institutions: University of Oklahoma Health Sciences Center (Oklahoma City, OK), Oklahoma City Veterans Health Care System (Oklahoma City, OK), Barshop Institute for Longevity and Aging Studies at UT Health San Antonio (San Antonio, TX), University of Washington School of Medicine (Seattle, WA), University of Buenos Aires (Buenos Aires, Argentina), and Institute of Biology and Experimental Medicine, CONICET (Buenos Aires,Argentina).
  • Countries: United States and Argentina.
  • Journal and Impact Evaluation: Posted on bioRxiv, a preprint repository.

Related Reading:

RapAdmin

Lithuanian researchers measured total NAD (NAD+ plus NADH) in finger-prick dried blood spots from 1,068 adults to test a core assumption of the supplement industry: that NAD falls with age. In people without chronic disease, it did not. Levels were flat across age in men and rose slightly in women, and men averaged about 14 percent higher than women. Adults treated for cardiovascular disease, especially hypertension, had blood NAD roughly 10 to 15 percent lower than healthy peers. In men with chronic disease, levels drifted down with age. Small exploratory studies showed that NAD varies by 2 to 3 µM within one person over a week, and that 1,000 mg/day of NMN nearly tripled blood NAD within about two weeks. Because the design is cross-sectional, the data cannot show whether low NAD contributes to vascular disease or results from it, or from its treatment.

For more than a decade, the pitch for NAD boosters has rested on a simple story. NAD, a molecule every cell needs to turn food into usable energy, drains away as we age, and topping it up with precursors such as NMN or NR should slow the clock. Tissue studies support part of that story: NAD does appear to fall in aging muscle, brain and skin. Blood, the only compartment most people can easily test, has produced contradictory results.

A team from Vilnius University and two Lithuanian diagnostics companies has now added the largest dataset so far. Participants pricked a finger after an overnight fast and mailed a blood-spot card to the lab. Among the 707 people with no chronic disease and no supplement use, age made no difference in men. In women, NAD crept upward by about 0.07 µM per year, roughly 2.8 µM over four decades.

The disease data point in another direction. People on medication for cardiovascular disease had lower blood NAD than healthy peers, and hypertension gave the clearest signal. Women with treated high blood pressure ran about 14 percent below an age-matched healthy reference, and men about 10 percent below. Treated high cholesterol showed no reduction, and neither did thyroid disease. In men with chronic disease, NAD fell steadily with age, while healthy men stayed flat.

The authors think this explains why earlier blood studies disagreed. Hypertension becomes more common with every decade of life. A study that samples the general population without separating out cardiovascular patients would see what looks like an age-related decline but is really a disease effect. The idea is plausible and testable. It also lines up with a Dutch study published in the same journal earlier this year, which used a different laboratory method and also found whole-blood NAD+ stable across age.

Two smaller experiments add detail. Repeated sampling showed that one person’s NAD can swing 2 to 3 µM over a week, about the same size as the gap between the healthy and hypertensive groups. Two volunteers taking 1,000 mg of NMN daily saw blood NAD climb from about 20 to over 50 µM, levelling off in roughly two weeks. A handful of supplement users in the main cohort reached similar levels, two to three times anything seen in the unsupplemented population.

The authors are clear about what they did not show. They did not test whether raising NAD lowers blood pressure, and they say the long-term effects of holding blood NAD at levels the body never normally reaches are unknown. Readers should also know two things. Most of the authors work for the company that makes the test kit. And hematocrit, the share of blood made up of red cells, where nearly all blood NAD sits, was never measured.

The big idea is a reframing. Blood NAD looks less like an aging clock and more like a modest signal of cardiovascular health. For healthy people under about 65, the paper removes the main blood-based argument for taking NAD precursors just because they are getting older.

Actionable Insights

  1. Getting older is not, by itself, a blood-based reason to supplement. In healthy men aged 20 to 65, blood NAD changed by only 0.002 µM per year, about 0.08 µM over 40 years, which is effectively zero. This says nothing about muscle or brain NAD.
  2. Blood pressure is the variable that mattered most here. Treated hypertension was linked to NAD that was 2.1 µM (10.5%) lower in men and 2.8 µM (14.5%) lower in women. Put another way: pick one hypertensive and one healthy person at random, and the hypertensive person has the lower NAD only about 64 to 69 percent of the time, where 50 percent would be a coin toss. That is a modest effect. Proven ways of controlling blood pressure stay first in line. The evidence that NAD precursors lower blood pressure rests mainly on one small pilot, in which systolic pressure fell about 8 to 10 mmHg in 13 people.
  3. If you test, test carefully. Daily swings of 2 to 3 µM are as large as the disease effect. Sample in the morning while fasted, repeat the test, and compare against values for your sex, since men ran about 14% higher.
  4. NMN at 1,000 mg/day raised blood NAD 2.6 to 3 fold and reached 90 to 95 percent of its plateau by day 14, so retest no sooner than two weeks. For the long-term safety of these levels, Safety Data Absent.

Context and Source

  • Open Access Paper: Whole-blood NAD levels track cardiovascular disease but not chronological age, published November 4, 2026.
  • Institutions: Life Sciences Center, Vilnius University; LifeLab1 (UAB “Laboratorija 1”); SensoLife (UAB “Bioanalizės sistemos”); Vilnius University Hospital Santaros Klinikos; Faculty of Medicine, Vilnius University
  • Country: Lithuania
  • Journal: Nature Metabolism
  • Funding and conflicts: No specific funding. Ten of the eleven authors are or were employees of SensoLife, the maker of the dried-blood-spot NAD kit used (SL2502), or of LifeLab1, the testing laboratory. Bloodo supplied the collection kits for free.
  • Impact evaluation: The impact score of this journal is 27.5 (2025 Journal Impact Factor, JCR 2026 release; up from 20.8 the year before), evaluated against a typical high-end range of 0-60+ for top general science, therefore this is a High impact journal.

Related Reading:

RapAdmin

Semaglutide produces dramatic weight loss, but how much of that loss comes from functional muscle remains contested, and nearly all rodent work to date has used young males. Researchers at the University of Utah treated 21-month-old obese mice, roughly equivalent to humans in their sixties, with daily semaglutide for three weeks. Fat loss was large in both sexes. The muscle picture split sharply by sex. Aged females lost up to 14 percent of quadriceps mass, a proportionally greater loss than their whole-body lean mass decline, yet their force production per unit area held steady. Aged males preserved muscle mass almost entirely but lost 19 percent of maximal force in one fast-twitch muscle. Critically, obesity did not inflate muscle mass in these older animals the way it does in young ones, so any loss dropped them below age-matched lean controls.

For two years the argument about GLP-1 drugs and muscle has run in circles. Clinical trials report that a quarter to forty percent of the weight lost on semaglutide is lean mass, which sounds alarming. Skeptics counter that lean mass measured by DEXA is a crude proxy that lumps skeletal muscle together with liver, gut, spleen, and body water, so a falling number does not necessarily mean a shrinking quadriceps. Mouse studies, where investigators can simply dissect and weigh each muscle, mostly supported the skeptics. The problem is that those mice were young.

This group, which published one of the reassuring young-mouse papers last year, went back and repeated the experiment in old animals. Male and female C57BL/6J mice were fattened on a high-fat diet from eighteen months of age, then given daily semaglutide at twenty-one months, an age the authors equate to a human in their sixties and deliberately chosen to sit before the onset of frank sarcopenia in this strain. The design was otherwise identical to the young-mouse study, which makes the comparison unusually clean.

Fat loss was not the issue. It was large, dose dependent, and similar in both sexes. What changed with age was where the rest of the weight came from, and whether there was any cushion underneath.

In young obese mice, high-fat feeding itself builds muscle. The animals are carrying more load and eating more calories, so their muscles grow. When semaglutide then trimmed a few percent off, the muscles simply returned to the size of lean controls, and nothing looked lost. In these aged mice that padding was absent. High-fat feeding did not enlarge a single limb muscle. So when semaglutide took mass off, the animals ended up below their age-matched lean counterparts rather than back at par. That single observation is the paper’s most consequential point, and it does not depend on any sex comparison.

The sex findings are the attention-grabbing part, and they run in opposite directions. Aged females showed the muscle wasting: quadriceps down 14.2 percent, gastrocnemius down 9.4 percent, with individual fiber cross-sectional areas shifted smaller. Several muscles lost a larger percentage than whole-body lean mass did, which inverts the pattern seen in young animals. Yet when those muscles were mounted on a force transducer, they pulled as hard per unit area as controls. Aged males showed the mirror image: muscle masses essentially intact, but maximal specific force in the extensor digitorum longus down 19.2 percent, a strength deficit in a muscle that had not shrunk at all.

That dissociation is biologically interesting and statistically fragile. Smaller muscles that work fine, and normal-sized muscles that do not, are both plausible aging phenotypes, but with five to ten animals per group and borderline p values, either result could soften on replication. The authors are appropriately cautious, calling for clinical trials that use magnetic resonance imaging or D3-creatinine dilution and that deliberately enroll older adults. Given that a 7.2 milligram semaglutide dose is now approved, roughly matching the high dose used here, that call is timely.

Actionable Insights

Effect sizes here are large by conventional standards but rest on very small groups, so treat them as signals rather than settled magnitudes.

The strongest signal is about reserve, not drug toxicity. In old mice, obesity no longer inflates muscle mass, so weight loss cuts into baseline rather than into surplus. The practical translation: if you are over sixty and starting a GLP-1, you probably do not have the muscle buffer a forty-year-old has.

Dose appeared to matter in males. At the low dose, male quadriceps and lean mass were barely touched (lean mass down 2.3 percent, Cohen’s d of 0.41, which is a small effect). At the high dose, lean loss tripled to 6.6 percent (d of 1.07, a large effect). Females showed no such dose separation, losing roughly 8.5 percent of lean mass at both doses.

A Cohen’s d of 1.0 means the average treated animal sits a full standard deviation below the average control, outside roughly 84 percent of the control distribution. That is a real difference, not a statistical artifact.

Two monitoring implications. First, track function, not only the scale: the male strength loss occurred in a muscle that had not shrunk, so mass measurements would have missed it entirely. Second, appetite suppression was concentrated in week one and food intake normalized by week two, which identifies the early phase as the window where protein intake and resistance loading most need protection.

Context and Source

  • Open Access Paper: Aging exacerbates muscle loss induced by semaglutide treatment in female mice.
  • Institution: Center of Metabolic Health, Department of Nutrition and Integrative Physiology, Molecular Medicine Program, Department of Pathology, and Department of Biochemistry, University of Utah, Salt Lake City, Utah, United States.
  • Journal: None. bioRxiv is a preprint repository.
  • Impact Evaluation: None. bioRxiv is a preprint repository.

RapAdmin

A structured narrative review in Sports argues that a man’s circulating testosterone, if it falls within the normal range, carries almost no information about how much muscle he will gain from resistance training. Across six training cohorts of 195 young men, the authors report correlations between baseline total testosterone and hypertrophy of plus 0.06 and minus 0.05, indistinguishable from zero. Injected testosterone behaves differently: across fourteen dose arms from three hormonally clamped trials, lean mass rose about 1.81 kilograms per doubling of weekly dose, with no ceiling up to 600 milligrams. Below the clinical floor, two small suppression trials blunted the training response by 43 and 73 percent without abolishing it. The authors propose a three-phase model: testosterone is limiting when severely deficient, permissive across the normal male range, and a graded pharmacological driver when administered.

The big idea here is a separation that the fitness and anti-aging worlds have spent decades collapsing into one claim. Testosterone as a drug and testosterone as a measurement are not the same thing, and only one of them predicts muscle growth.

As a drug, testosterone works, and it works in proportion to dose. The authors pooled fourteen dosing arms from three trials in which researchers shut down the subjects’ own hormone production and then replaced it at fixed weekly amounts ranging from 25 to 600 milligrams. Lean mass tracked the dose with almost mechanical regularity, rising roughly 1.81 kilograms each time the weekly dose doubled, while fat mass fell about one kilogram per doubling. Nobody in these trials lifted weights. There was no sign of a ceiling at the top of the range, which fits what is observed in enhanced bodybuilding, where doses run well past the highest studied here.

As a measurement in a man whose body makes its own testosterone, the number tells you close to nothing about his training response. Six longitudinal cohorts measured baseline testosterone and then put men through resistance training programs lasting six to twenty weeks. Not one found a positive association with muscle growth. The two cohorts whose raw data the authors reanalyzed produced correlations of plus 0.055 and minus 0.049, which bracket zero from either side. Two young men sitting at opposite ends of the normal male reference window, 264 and 916 nanograms per deciliter, can be expected to gain statistically indistinguishable amounts of muscle.

The acute version of the hypothesis fares no better. The idea that you should train legs to grow arms, or chase a post-workout hormonal surge, was tested directly by training one arm of each subject under a low-hormone protocol and the other under a high-hormone protocol. The hormonal responses diverged sharply. The muscle growth did not differ. The authors calculate that the post-exercise bump, typically 10 to 30 percent for under an hour, adds something on the order of a tenth of a percent to daily androgen exposure. Some of that bump is not even hormone, just blood concentrating as fluid leaves the plasma.

Below the clinical floor the picture changes again. Two trials chemically suppressed healthy men to castrate levels and then trained them. The training response was cut by 43 and 73 percent, yet in one of them lean mass still rose significantly. Men on long-term androgen deprivation for prostate cancer also still gain lean mass from exercise, roughly 0.9 to 1.1 kilograms across several meta-analyses, against about 1.5 kilograms in intact men.

Put together, testosterone looks less like a throttle and more like a fuse. Below a certain point the system runs at reduced capacity. Above it, more does not mean more, and whatever separates a high responder from a low responder lives somewhere else, in mechanical signaling, ribosome production, satellite cell capacity, and motor unit recruitment.

Actionable Insights

Four take-homes.

First, if your total testosterone sits anywhere in the normal range, stop treating it as a forecast of your training response. The measured association explains about 0.3 percent of the person-to-person variation in muscle growth (correlation 0.055). By contrast, twelve weeks of training in recreationally trained men produced size increases of 10 to 17 percent, an effect size of 0.5 to 0.7, which counts as moderate. The training signal is measurable. The hormone signal is not.

Second, the post-workout hormone surge is not worth programming around. It adds roughly 0.1 to 0.3 percent to daily androgen exposure, and a direct within-person test found no difference in growth.

Third, training dominates hormone level. Men suppressed to 32 nanograms per deciliter who trained gained 1.3 kilograms of lean mass in eight weeks. Men at 175 nanograms per deciliter who did not train lost 0.3 kilograms.

Fourth, if you are genuinely below the clinical floor, expect a blunted but working response, roughly 40 to 70 percent of normal, and keep training. That attenuation is an effect size near 0.8 to 1.1, which is large, but it rests on two trials with roughly 10 men per group, so treat the percentages as approximate.

Context and Source

  • Open Access Paper: Do Serum Testosterone Values Potentiate or Predict Muscle Hypertrophy? A Structured Narrative Review
  • Authors and institutions: Benjamin T. House, Thomas R. Wood, Federica Conti, Andrew J. Galpin. Primary affiliation BioMolecular Athlete, Austin, Texas. Secondary affiliations Department of Pediatrics, Division of Neonatology, and Institute on Human Development and Disability, University of Washington, Seattle.
  • Country: United States
  • Journal: Sports (MDPI, Basel, Switzerland)
  • Impact evaluation: The impact score of this journal is 3.2 (2025 Journal Impact Factor, released June 2026), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a Low impact journal.

RapAdmin

In this Nature Aging review, Andrew Steptoe and Daisy Fancourt of University College London synthesize evidence that social isolation, which affects roughly one in four adults over 60, is associated with a 30 to 40 percent higher risk of death, along with elevated risks of heart disease, stroke, dementia, depression and frailty. They catalogue biological correlates spanning cortisol, inflammation, blood pressure, the gut microbiome, plasma proteomics and epigenetic clocks, while stressing that most human data are observational and vulnerable to reverse causation. Their central argument is that community leisure engagement (arts groups, volunteering, libraries, sports clubs, nature walks) is an underappreciated and highly modifiable component of isolation. Observational studies link such activities to 15 to 35 percent lower mortality. The authors call for stronger causal designs and for rigorous evaluation of the social prescribing programs now spreading across more than 30 countries.

Longevity enthusiasts tend to measure their progress in milligrams and minutes: doses of rapamycin, grams of protein, zone 2 sessions. A new review in Nature Aging argues that one of the larger modifiable risk factors for an early death does not fit in a pill organizer at all. It is how often you leave the house to do things with other people.

The authors, Andrew Steptoe and Daisy Fancourt, are leading social epidemiologists; Steptoe designed one of the most widely used isolation scores in aging research. Their review pulls together several large meta-analyses that converge on a consistent finding. Older adults who are socially isolated, meaning they live alone, have little contact with family and friends, and take little part in community life, face a 30 to 40 percent higher risk of dying over follow-up periods of several years. The pattern holds in high-income countries and in places such as India, Bangladesh, Tanzania, Mexico and China. Isolation is also tied to coronary heart disease, stroke, depression, frailty and cognitive decline, and greater social participation in mid and later life is associated with a 30 to 50 percent lower risk of dementia.

The biology is plausible. Isolated people show higher cortisol, exaggerated blood pressure responses to stress, reduced heart rate variability, higher inflammatory markers, gut microbiome changes, lower grip strength, endothelial dysfunction and older biological age on epigenetic clocks. A UK Biobank study identified 175 blood proteins linked to isolation, including proteins in antiviral, complement and clotting pathways, many of which themselves predict diabetes, heart disease and death.

The authors are candid about the weak spots. Sick people withdraw from social life, so illness may cause isolation rather than the reverse. Inflammation itself makes people feel socially disconnected. Animal experiments that prove causation use enforced solitary housing, closer to solitary confinement than to a widow living alone. Genetic studies using Mendelian randomization sometimes agree with the observational findings and sometimes do not.

The big idea of the paper is a reframing. Most isolation scores already include questions about clubs, cultural outings and group membership, so community leisure is mathematically baked into the risk factor. It is also the part that is easiest to change. You cannot easily acquire a spouse or a larger family, but you can join a choir. Studies of arts engagement, hobbies and gardening report mortality hazard ratios around 0.65 to 0.85, similar in size to the isolation effect running in the opposite direction. One 19-country analysis found that starting a hobby was linked to substantially lower mortality, keeping it up was linked to even lower risk, and stopping it erased the association completely.

Governments are already acting, through free museum schemes in England, Singapore and Mexico and social prescribing systems in which doctors refer patients to walking groups, art classes and volunteering. The authors warn that many well-intended programs have failed in trials and that rigorous testing, ideally including biological outcomes, should come first.

The honest bottom line is that the association between social isolation and death is large, consistent and global. Whether adding community activities late in life will buy you extra years remains to be proven in a randomized trial.

Actionable Insights

  1. Treat regular group activity as a health behavior. Frequent cultural engagement (every few months or more) was linked to a 31 percent lower risk of death over 14 years in English adults over 50, or about 2.4 versus 6.0 deaths per 1,000 people per year compared with never attending. On a standardized scale this is a small effect (roughly d = 0.20), comparable to many accepted lifestyle factors.
  2. Consistency matters more than intensity. In 79,464 adults across 19 countries, any hobby engagement was linked to 29 percent lower mortality; sustaining a hobby was associated with 55 percent lower risk, and quitting removed the benefit entirely. Part of that gap probably reflects people quitting because they became ill.
  3. Diversify. Biological and isolation outcomes look best among people with frequent and varied engagement, not a single weekly activity.
  4. Plan for transitions. Retirement, bereavement, children leaving home, hearing loss and mobility limits raise isolation risk. Treating hearing loss and arranging transport are practical levers.
  5. Calibrate expectations. Isolation carries roughly a 32 percent higher mortality risk (d of about 0.15). For a 70-year-old with a 20 percent ten-year risk of death, that is about 5 extra deaths per 100 people. Real, but not proven to be reversible by adding activities.

Context and Source

  • Paywalled Paper: Social isolation, community leisure engagement and the social determinants of healthy aging
  • Article type: Review article
  • Institution: Department of Behavioural Science and Health, University College London
  • Country: United Kingdom
  • Journal: Nature Aging, Volume 6, November 2026.
  • Impact Evaluation: The impact score of this journal is 25.0, evaluated against a typical high-end range of 0 to 60+ for top general science and medicine journals, therefore this is a High impact journal.

Related Reading:

RapAdmin

In this Nature Aging review, Rachel Winterton of La Trobe University and colleagues from China, South Africa, Canada and Ireland propose a framework of the social determinants of rural healthy aging. Drawing on a healthy aging model developed with the World Health Organization, they sort determinants into structural factors (policy framings that cast rural aging as a problem, spatial and environmental characteristics, ageist and idealized rural stereotypes, and socioeconomic and demographic positions) and intermediary factors (health and aged care services, built and natural environments, community capacity to mobilize, and individual strengths such as mobility, social networks, digital literacy and fit with place). Their central conclusion is that rurality is not inherently linked to poor health in later life. Inequities arise from service gaps, socioeconomic disadvantage, mobility constraints, environmental exposures and social exclusion, which are shaped by local context, and especially by differences between high-income and low- and middle-income countries.

The image of rural old age tends to swing between two cliches. One is the rural idyll, in which close-knit villages, clean air and quiet lanes let people grow old gracefully. The other is the forgotten countryside, in which hospitals close, buses stop running and the young leave. A new review in Nature Aging argues that both pictures are wrong, or at least incomplete.

Rachel Winterton, a rural aging researcher at La Trobe University in Australia, and colleagues from Beijing Normal University, North-West University in South Africa, Trent University in Canada and the University of Galway in Ireland set out to map what actually drives health differences among older people living in rural places. Their conclusion is blunt: rural demography and geography are not destiny. Older people are not disadvantaged simply because they live in the countryside.

What matters more are the conditions that often, but not always, come with rural life. Health and aged care services are harder to staff and more expensive to run at small scale, so people travel further and wait longer. Public transport is sparse, which makes the ability to drive or walk central to getting food, medicine and company. Many rural places have lower incomes and education levels, and older residents often worked in hazardous outdoor or agricultural jobs. Climate change brings more fires, floods, droughts and heat, with fewer resources to respond. Internet access and digital skills lag, just as services move online.

The authors are equally clear about the strengths. Long attachment to a place, close neighbors and volunteer networks often compensate for missing services. Some remote settlements rate better on participation and healthcare access than towns closer to cities. Wealthier retirees who move to amenity-rich rural areas do not carry a lifetime of rural disadvantage.

Context changes everything. In wealthy countries, rural inequities stem from centralized services, market-based aged care and assumptions that infrastructure exists for aging in place. In low- and middle-income countries, older rural people often lack pensions, work into old age, raise grandchildren left by HIV, COVID-19 or migration, and depend on subsistence farming.

The review also criticizes policy. Governments tend to frame rural aging as a burden and push responsibility onto older people and their communities to fill service gaps, while the World Health Organization’s age-friendly cities model carries an urban bias.

The authors set out six priorities: define and measure rurality properly; work out which features of rural life actually drive disparities and for whom; make age-friendly policies sensitive to rural realities; make rural policies sensitive to older people; understand how lifelong rural exposures shape individual strengths and vulnerabilities; and anticipate how rural change creates new inequities.

The paper is a thoughtful conceptual synthesis from leading rural gerontologists. Its most practical message is that the person, their resources and their fit with place matter more than a rural postcode.

Actionable Insights

  1. Resources matter more than postcode. Among 28,235 Chinese adults aged 65 and older, rural residents had about 12 percent higher mortality than urban residents after adjusting for demographics (a trivial effect, d of about 0.06). The gap disappeared once education, income and healthcare access were accounted for.
  2. Income drives much of the mood gap. In a national Chinese survey, depressive symptoms affected 12.4 percent of rural versus 10.1 percent of urban older adults. About 74 percent of the difference was explained by measurable factors, with income alone accounting for nearly a third.
  3. Protect mobility. Where public transport is sparse, the ability to drive or walk determines access to food, care and company. Strength, balance and vision are therefore access issues, not just fitness goals.
  4. Build networks and digital skills. Neighbors, family and volunteer groups fill gaps where services are thin, and telehealth increasingly depends on reliable internet and confidence using it.
  5. Reassess your fit with place as needs change, and plan for fire, flood and heat events, before a crisis forces a move.

Context and Source

  • Paywalled Paper: Conceptualizing the social determinants of rural healthy aging
  • Institution: John Richards Centre for Rural Ageing Research, La Trobe Rural Health School, Bendigo, Victoria (lead and corresponding). Co-authors from Beijing Normal University, North-West University (South Africa), Trent University (Canada) and the Irish Centre for Social Gerontology, University of Galway.
  • Country: Australia (with China, South Africa, Canada and Ireland)
  • Journal: Nature Aging, Volume 6, November 2026.
  • Impact Evaluation: The impact score of this journal is 25.0, evaluated against a typical high-end range of 0 to 60+ for top general science and medicine journals, therefore this is a High impact journal.

RapAdmin

In this Nature Aging Perspective, Joaquin Migeot, Agustin Ibanez and an international team that includes Terrie Moffitt, Eileen Crimmins, Arline Geronimus, Carol Brayne and Kristine Yaffe argue that research on how social determinants of health shape brain aging and dementia is skewed toward wealthy Western populations and relies too heavily on single proxies such as years of education or income. They review composite indices of social disadvantage, call for harmonized but locally validated measures, and describe how adversity may become biologically embedded through stress hormones, inflammation, metabolic and vascular dysfunction and epigenetic change. They also discuss gene-environment interaction, the analytical challenge of modeling cumulative and nonlinear exposures, and propose a three-tier implementation pathway suited to low-resource settings.

Two people may have the same number of years of schooling, but one studied in a well-funded school in Oslo and the other in an overcrowded classroom in a city marked by violence and pollution. Should researchers treat their “education” as the same risk factor for dementia? A new Perspective in Nature Aging argues that they should not, and that this kind of mismatch is distorting our picture of who develops dementia and why.

The authors, led by neuroscientist Agustin Ibanez of the Latin American Brain Health Institute in Chile and the Global Brain Health Institute in Dublin, point out that most dementia research comes from the Global North, while most of the world’s older adults will soon live in the Global South, where dementia is rising fastest. In these regions, poverty, informal work, weak social protection, violence, infectious disease and pollution tend to cluster. The same indicator can carry very different weight in different places.

They highlight striking associations. In South Africa, multidimensional poverty was linked to more than double the odds of screening positive for dementia. In Latin America, social conditions explained more variation in dementia prevalence than genetic ancestry. A recent 34-country study from the same research group found that combining physical, social and political exposures explained up to 15.5 times more variance in brain aging than any single exposure.

The paper describes how social hardship may get “under the skin”. Repeated stress keeps the body’s main stress-hormone system switched on, flooding the brain with cortisol and affecting memory and emotion circuits. Inflammation, insulin resistance, vascular damage, faster epigenetic clocks and shorter telomeres follow. Co-author Arline Geronimus’s concept of “weathering” describes how constant adaptation to structural disadvantage wears down the body over decades.

On the practical side, the authors discuss multidomain prevention trials. Finland’s FINGER trial, the US POINTER trial and co-author Kristine Yaffe’s SMARRT trial all found that structured or personalized programs combining exercise, diet, cognitive and social engagement and medical risk management improved cognition modestly. The catch is that these programs depend on individuals changing behavior, which is hardest for people facing food insecurity, unsafe streets or limited healthcare. The authors argue that policy-level change, such as compulsory schooling reforms or poverty alleviation, needs to sit alongside individual programs.

They propose a pragmatic three-tier plan. Tier 1, feasible now everywhere, uses short surveys on education quality, financial strain, food insecurity, housing, healthcare access, discrimination, trauma and isolation. Tier 2 links people to census, pollution and green space data. Tier 3 adds genomics, epigenetics, wearables and digital twins where resources allow. They warn against “extractive” research in which data flow from the Global South while control and credit stay elsewhere.

The paper is a Perspective, not a systematic review. Its evidence table leans heavily on mental health studies in younger people rather than dementia, and much of the key brain-aging evidence comes from the authors’ own work. The central claim, that social context strongly shapes brain aging, is plausible and supported by consistent associations. Proof that changing that context will prevent dementia is still to come.

Actionable Insights

  1. Get structured support, not just good intentions. In the US POINTER trial (2,111 adults aged 60 to 79), a coached multidomain program improved global cognition by 0.029 standard deviations per year more than a self-guided version. That is very small (roughly d = 0.06 over two years), but it came at no extra harm.
  2. Personalize your risk targets. In SMARRT, 172 adults aged 70 to 89 with at least two risk factors (inactivity, high blood pressure, diabetes, poor sleep, cognition-impairing medications, depression, isolation, smoking) who received nurse coaching improved cognition by 0.14 standard deviations over two years versus controls: small but meaningful.
  3. Stay mentally and socially engaged. Cognitive and social activity show small associations with larger hippocampal volume (r = 0.07, d of about 0.14).
  4. Address stacked disadvantages. Multidimensional poverty carried about 2.3 times the odds of screening positive for dementia (moderate, d of about 0.46), suggesting that financial, housing and care stability matter.
  5. Do not treat genes as destiny. APOE e4 effects appear to vary with education, pollution and lifestyle.

Context and Source

  • Paywalled Paper: Social determinants of health and the exposome shape aging and dementia across global populations
  • Article type: Perspective (opinion and synthesis)
  • Institution: Latin American Brain Health Institute (BrainLat), Universidad Adolfo Ibanez, Santiago, and Global Brain Health Institute, Trinity College Dublin (lead). Co-authors from Utrecht, Barcelonabeta and Pompeu Fabra, Radboud, Universidad de San Andres, USC, Michigan, Duke, King’s College London, Oslo, Cambridge, UCSF and Istanbul Medipol.
  • Country: Chile and Ireland (lead institutions), with authors in Argentina, Spain, the Netherlands, the USA, the UK, Norway and Turkey
  • Journal: Nature Aging, Volume 6, November 2026.
  • Impact Evaluation: The impact score of this journal is 25.0, evaluated against a typical high-end range of 0 to 60+ for top general science and medicine journals, therefore this is a High impact journal.

RapAdmin

In this Nature Aging review, John S. Ji of Tsinghua University and an international team including Annette Peters and Andy Haines propose “environmental health resilience” as a framework for explaining why people facing similar air pollution, heat, toxic metals, unsafe water and poor housing age so differently. They separate three mechanisms that are often lumped together: population-wide exposure reduction, such as phasing out fossil fuels; individual exposure reduction, such as shade or air purifiers; and true effect modification, in which features such as green space, walkable design, social connection, fitness or diet flatten the exposure-response curve so that the same dose does less harm. The authors argue that both exposure reduction and resilience building are needed to compress morbidity. They acknowledge, however, that direct evidence for curve flattening exists mainly for green space and air pollution mortality, and remains sparse elsewhere.

Two neighbors breathe the same polluted air and swelter through the same heatwaves. Twenty years later one is frail and forgetful while the other still walks to the market every morning. Environmental health science has been very good at counting the damage from pollution and heat. A new review in Nature Aging asks a different question: what protects the people who escape it?

The lead author, John Ji, an environmental epidemiologist at Tsinghua University in Beijing, and colleagues from Australia, Germany, New Zealand, the UK and the World Health Organization call the answer “environmental health resilience”. Their key contribution is to separate three ideas that are usually blurred together.

The first is cutting exposure for everyone, for example through clean air laws or phasing out fossil fuels. The second is cutting an individual’s dose: a shady street, a cool roof or an air purifier lowers what you personally breathe or feel, even if the city’s pollution or temperature stays the same. The third, which the authors call resilience in the strict sense, is different. Here the dose stays the same but the body is harmed less, because something about the person’s surroundings or condition makes them better able to cope. On a graph, exposure reduction moves you along the risk curve, while resilience flattens the curve itself.

The review gives examples. Older adults are hit hardest by pollution and temperature extremes because their heart, lung, kidney and temperature-control reserves are shrinking. Yet aerobic fitness appears to be a stronger predictor of heat tolerance than age, which makes walkable neighborhoods a form of heat protection. During the 2021 British Columbia heat dome, people taking anti-Parkinson drugs, antiepileptics and some psychiatric medications had more than double the odds of dying from the heat. In a large Chinese cohort, high pollution was linked to cognitive decline mainly in people who ate few plant foods. Lead stored in bone from childhood exposure can leak back into the blood decades later during osteoporosis or frailty.

The authors are careful about one trap. At very high pollution levels, the risk curve appears to level off. That may look like resilience but probably reflects the fact that the most vulnerable people have already died, or that bodies under chronic assault have recalibrated in damaging ways. In those settings, cutting exposure must come first.

The scale of the problem is large. The review cites estimates that air pollution shortens average global life expectancy by nearly three years, and that non-optimal temperatures account for over 5 million deaths a year, most of them from cold rather than heat.

The weakness is evidence. The abstract claims these resilience factors flatten exposure-response curves, but the conclusion concedes that direct tests exist mainly for green space and air pollution mortality, with little for housing, urban design or social infrastructure. Some of the strongest supporting studies come from the lead author’s own group, and their effects are modest. The framework is useful. The proof is still being gathered.

Actionable Insights

  1. Get fit. Cardiorespiratory fitness appears to protect heat tolerance more than youth does. Habitual walking is heat protection as well as exercise.
  2. Review medications before heatwaves. Anti-Parkinson drugs, antiepileptics and psycholeptics each more than doubled the odds of heat-related death in British Columbia (a moderate effect, d of about 0.4). Strong anticholinergics and nonselective beta blockers impair cooling.
  3. Eat more plants. Among Chinese older adults, the highest pollution exposure raised the risk of poor cognitive function by 68 percent in those with low plant-based diet scores but only 28 percent (not statistically significant) in high scorers.
  4. Spend time in green space. Among China’s oldest-old, the greenest quarter of neighborhoods had 27 percent lower mortality than the least green (small effect, d of about 0.17).
  5. Clean your indoor air and keep warm. HEPA purifiers modestly lower blood pressure (about 3 mmHg in trials). Cold accounts for about nine times more temperature-related deaths than heat in one major estimate.

Context and Source

  • Paywalled Paper: Environmental health resilience and exposure reduction for healthy aging and longevity
  • Article type: Narrative Review
  • Institution: Vanke School of Public Health, Tsinghua University, Beijing (lead and corresponding). Co-authors from the University of Sydney, Tsinghua Department of Earth System Science, Helmholtz Munich, the WHO Department of Ageing and Health (Geneva), the University of Auckland and the London School of Hygiene and Tropical Medicine.
  • Country: China (with Australia, Germany, Switzerland, New Zealand and UK contributors)
  • Journal: Nature Aging, Volume 6, November 2026.
  • Impact Evaluation: The impact score of this journal is 25.0, evaluated against a typical high-end range of 0 to 60+ for top general science and medicine journals, therefore this is a High impact journal.

Related Reading: